Printer Friendly

LA JOLLA PHARMACEUTICAL LAUNCHES INFLAMMATION PROGRAM

 SAN DIEGO, May 6 /PRNewswire/ -- La Jolla Pharmaceutical Co. announced today that it has launched a program to develop inhibitors of the enzyme phospholipase A2 (PLA2) as potential treatments for inflammation and inflammatory diseases.
 LJP has exclusively licensed from the University of California a new class of chemical compounds (patents pending) which inhibit PLA2. The company has completed a new laboratory dedicated to inflammation research and has recruited a team to synthesize and test candidate molecules.
 PLA2 initiates the release of precursors which become potent inflammatory mediators. Diseases caused by inflammation include reheumatoid arthritis, osteoarthritis, asthma and inflammatory bowel diseases. The potential markets are large.
 "LJP's inflammation program is an extension of our current work to develop drugs based on our `Tolerance Technology(TM)' to treat antibody mediated diseases such as lupus. There are strong synergies both at the research level and in the nature of the target diseases. Our inflammation program has the potential to become a second core technology for the company," said Joseph Stemler, president and chief executive officer. "Because this project is a potential technology platform with a number of disease targets and significant markets, we shall welcome interest from corporate partners early in the program."
 La Jolla Pharmaceutical Co. was founded in 1989 to develop products based on its proprietary "Tolerance Technology" to treat antibody mediated diseases. The company is privately held and is headquartered in San Diego.
 -0- 5/6/93
 /CONTACT: Andrew Wiseman of La Jolla Pharmaceutical, 619-452-6600/


CO: La Jolla Pharmaceutical Co. ST: California IN: MTC SU:

LS-JB -- SD002 -- 5149 05/06/93 06:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 6, 1993
Words:264
Previous Article:SUN TO CONVERT ATLANTIC BRAND TO SUNOCO, SUNOCO FOOD MARKETS TO A-PLUS
Next Article:BIOSYS ANNOUNCES CONTRACT MANUFACTURING AGREEMENT WITH CIBA-GEIGY
Topics:


Related Articles
DR. THOMAS H. ADAMS ELECTED TO LA JOLLA PHARMACEUTICAL BOARD
LA JOLLA PHARMACEUTICAL CO. ANNOUNCES SECOND GENERATION MOLECULE TO TREAT LUPUS
ROBERT J. TERNANSKY, Ph.D., JOINS LA JOLLA PHARMACEUTICAL TO HEAD INFLAMMATION PROGRAM
La Jolla Pharmaceutical's Lupus Candidate Improved Both Antibody and Inflammation Related Complement Levels
La Jolla Pharmaceutical Initiates Phase II/III Clinical Trial for Lupus Drug

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters